Case series: Teriflunomide therapy in COVID-19 patients with MS

Co-authors present the cases of five multiple sclerosis patients who developed COVID-19 infection while taking the oral disease-modifying therapy teriflunomide and continued taking the medication. All five patients had favorable outcomes, with their COVID-19 taking a mild course and without experiencing relapse of their MS.